Brief: Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review
13/06/2025 07:08
June 13 (Reuters) - BioArctic AB BIOAb.ST: TO INITIATE NEXT COHORTS IN EXIDAVNEMAB PHASE 2A STUDY AFTER POSITIVE SAFETY REVIEW Source text: ID:nWkrJ5Ctj Further company coverage: BIOAb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln